BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 12865871)

  • 1. Is there a role for (99m)Tc-anti-CEA monoclonal antibody imaging in the diagnosis of recurrent colorectal carcinoma?
    Fuster D; Maurel J; Muxí A; Setoain X; Ayuso C; Martín F; Ortega ML; Fuertes S; Pons F
    Q J Nucl Med; 2003 Jun; 47(2):109-15. PubMed ID: 12865871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoscintigraphy with 99Tcm-labelled monoclonal anti-CEA BW 431/26 antibodies in patients with suspected recurrent and metastatic colorectal carcinoma: two-year follow-up.
    Lacić M; Bokulić T; Lukac J; Baum RP; Kusić Z
    Nucl Med Commun; 1999 Sep; 20(9):859-65. PubMed ID: 10533193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
    Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
    J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels.
    Patt YZ; Podoloff DA; Curley S; Kasi L; Smith R; Bhadkamkar V; Charnsangavej C
    J Clin Oncol; 1994 Mar; 12(3):489-95. PubMed ID: 8120546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of radioimmunoscintigraphy with technetium-99m labelled anti-CEA monoclonal antibody (BW431/26) in the detection of colorectal cancer.
    Poshyachinda M; Chaiwatanarat T; Saesow N; Thitathan S; Voravud N
    Eur J Nucl Med; 1996 Jun; 23(6):624-30. PubMed ID: 8662095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99m-monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma.
    Lind P; Lechner P; Arian-Schad K; Klimpfinger M; Cesnik H; Kammerhuber F; Eber O
    J Nucl Med; 1991 Jul; 32(7):1319-25. PubMed ID: 2066784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA.
    Hertel A; Baum RP; Lorenz M; Baew-Christow T; Encke A; Hör G
    Br J Cancer Suppl; 1990 Jul; 10():34-6. PubMed ID: 2166552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of colorectal carcinoma by anti-CEA monoclonal antibody (IOR-CEA1) labeled with 99mTc scintigraphy.
    Sirisriro R; Boonkitticharoen V; Kraiphibul P; Ratanatharathorn V; Sumboonnanon K; Kanjanapitak A; Kuhapremma T; Sritara C; Puchinda D; Chouplywech P; Jalayondeja V; Pekanan P; Rochanawutanon M; Intaramarn C; Ayudhya AN; Chokesuwathana P
    Hepatogastroenterology; 2000; 47(32):405-13. PubMed ID: 10791201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen (CEA) scan in the diagnosis of recurrent colorectal carcinoma in a patient with increasing CEA levels and inconclusive computed tomographic findings.
    Ghesani M; Belgraier A; Hasni S
    Clin Nucl Med; 2003 Jul; 28(7):608-9. PubMed ID: 12819425
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of CEA immunoscintigraphy for diagnosis of colorectal cancer and its metastases: results of a prospective study].
    Imdahl A; Bräutigam P; Hauenstein KH; Eggstein S; Waninger J; Farthmann EH
    Zentralbl Chir; 1994; 119(1):17-22. PubMed ID: 8147155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of immunoscintigraphy for the operative retreatment of colorectal cancer. Limitations of a new diagnostic method.
    Hölting T; Schlag P; Steinbächer M; Kretzschmar U; Georgi P; Herfarth C
    Cancer; 1989 Aug; 64(4):830-3. PubMed ID: 2743277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
    Doerr RJ; Herrera L; Abdel-Nabi H
    Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 99Tcm-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management.
    Sirisriro R; Podoloff DA; Patt YZ; Curley SA; Kasi LP; Bhadkamkar VA; Kim EE; Murray JL; Smith R; Haynie TP
    Nucl Med Commun; 1996 Jul; 17(7):568-76. PubMed ID: 8843115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection efficiency of colorectal carcinoma recurrence using technetium pertechnetate-anti-carcinoembryonic antigen monoclonal antibody BW 431/26.
    Zwas ST; Goshen E; Rath P; Brenner H; Klein E; Ben-Ari G
    Cancer; 1995 Jul; 76(2):215-22. PubMed ID: 8625094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of immunoscintigraphy using a cocktail of radiolabeled monoclonal antibodies in the detection of colorectal cancer.
    Volpe CM; Abdel-Nabi HH; Kulaylat MN; Doerr RJ
    Ann Surg Oncol; 1998 Sep; 5(6):489-94. PubMed ID: 9754756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful immunoscintigraphic tumor detection with technetium 99m marked monoclonal anti-CEA antibodies].
    Baum RP; Lorenz M; Hertel A; Baew-Christow T; Schwarz A; Hör G
    Onkologie; 1989 Aug; 12 Suppl 1():26-9. PubMed ID: 2685692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.